611
Participants
Start Date
May 3, 2022
Primary Completion Date
August 19, 2026
Study Completion Date
August 19, 2026
pembrolizumab/vibostolimab
Administered as an intravenous (IV) infusion
durvalumab
Administered as an IV infusion
cisplatin
Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
pemetrexed
Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
etoposide
Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
carboplatin
Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
paclitaxel
Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
thoracic radiotherapy
60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
Veterans Memorial Medical Center-Section of Oncology ( Site 3201), Quezon City
THE MEDICAL CITY-Cancer Research Center ( Site 3200), Pasig
Canberra Hospital ( Site 0010), Canberra
St Vincent's Hospital-Oncology Clinical Trials ( Site 0005), Melbourne
Frankston Hospital-Oncology and Haematology ( Site 0009), Frankston
Ballarat Health Services-Medical Oncology ( Site 0002), Ballarat Central
Abraham Oncology ( Site 2303), Richards Bay
The Oncology Centre ( Site 2300), Durban
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2304), Port Elizabeth
Icon Cancer Centre Hobart ( Site 0003), Hobart
Cape Town Oncology Trials ( Site 2306), Cape Town
Icahn School of Medicine at Mount Sinai ( Site 2821), New York
Instituto de Oncologia ( Site 3003), Santo Domingo
CIMCA ( Site 0501), San José
Onconet ( Site 3002), Distrito Nacional
Hospital Pulau Pinang ( Site 1400), George Town
White Plains Hospital ( Site 2835), White Plains
Hospital Metropolitano - Sede Lindora ( Site 0503), Santa Ana
PROCLINICAL Pharma ( Site 0504), San José
Sotiria Thoracic Diseases Hospital of Athens ( Site 0704), Athens
Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 0603), Berlin
CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2502), Santiago de Compostela
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2401), Suwon
Ajou University Hospital-Hematology-Oncology ( Site 2402), Suwon
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827), Lancaster
Thomas Jefferson University - Clinical Research Institute ( Site 2813), Philadelphia
Ospedale San Raffaele. ( Site 1104), Milan
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1100), Milan
Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1102), Monza
"Communal Noncommercial Enterprise Podillia Regional Oncology Center Of Vinnytsia Regional Council ( Site 2900)", Vinnytsia
MFSMC-HJWCI ( Site 2804), Baltimore
LungenClinic Grosshansdorf-Onkologie ( Site 0602), Großhansdorf
Universitaetsklinikum Schleswig-Holstein Campus Kiel-Medizinische Klinik II, Hämatologie und Onkolo ( Site 0609), Kiel
Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 2905), Kropyvnytskyi
Azienda Ospedaliera Spedali Civili di Brescia ( Site 1105), Brescia
Fondazione IRCCS Policlinico San Matteo ( Site 1103), Pavia
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2504), Pozuelo de Alarcón
Chungbuk National University Hospital-Internal medicine ( Site 2400), Cheongju-si
Centro Oncologico de Chihuahua-Unidad de Investigacion Clinica ( Site 1507), Chihuahua City
Mid Florida Hematology and Oncology Center ( Site 2800), Orange City
Rivne Regional Clinical Hospital ( Site 2919), Rivne
Millennium Oncology Research Clinic ( Site 2801), Hollywood
Moffitt Cancer Center ( Site 2818), Tampa
Medipol Mega Universite Hastanesi-oncology ( Site 2611), Stanbul
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2610), Istanbul
Ege University Medicine of Faculty-Chest Diseases Department ( Site 2603), Bornova
I.E.U. Medical Point Hastanesi-Oncology ( Site 2612), Izmir
Volyn Regional clinical hospital. Regional Medical Oncology Centre. Oncology chemotherapy department ( Site 2918), Lutsk
Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 1505), Guadalajara
Franciscan St. Francis Health ( Site 2812), Indianapolis
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1401), Kuala Lumpur
University Malaya Medical Centre-Clinical Oncology ( Site 1402), Lembah Pantai
University of Chicago Medical Center ( Site 2828), Chicago
University of Missouri Hospital ( Site 2839), Columbia
Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837), Springfield
Centro de Investigacion Clinica de Oaxaca ( Site 1501), Oaxaca City
Central Texas Veterans health care-Oncology & Hematology ( Site 2819), Temple
Millennium Research & Clinical Development ( Site 2811), Houston
"Municipal non-profit enterprise Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 2920)", Lviv
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia medica Toraco-Polmonare ( Site 1107), Napoli
VA West Los Angeles Medical Center ( Site 2808), Los Angeles
VA Long Beach Healthcare System ( Site 2831), Long Beach
Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816), Portland
MultiCare Health System ( Site 2817), Tacoma
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 0328), Beijing
Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309), Beijing
Beijing Peking Union Medical College Hospital-pneumology department ( Site 0300), Beijing
Jilin Cancer Hospital-oncology department ( Site 0319), Changchun
Shanghai Chest Hospital-Radiotherapy Department ( Site 0306), Shanghai
Fudan University Shanghai Cancer Center ( Site 0304), Shanghai
Shanghai Pulmonary Hospital-Radiotherapy department ( Site 0335), Shanghai
"Centrul de Oncologie Sfântul Nectarie ( Site 2100)", Craiova
Affiliated Hospital of Jiangsu University ( Site 0305), Zhenjiang
The Second Affiliated Hospital of Soochow University ( Site 0314), Suzhou
Shandong Provincial Hospital ( Site 0326), Jinan
Qingdao Central Hospital-Endocrinology ( Site 0332), Qingdao
Tianjin Cancer Hospital ( Site 0329), Tianjin
Cabinet Medical Oncomed ( Site 2101), Timișoara
Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou
Zhejiang Cancer Hospital ( Site 0308), Hangzhou
Fujian Medical University Union Hospital-1 Bingfanglou ( Site 0330), Fuzhou Fujian
Fujian Provincial Cancer Hospital ( Site 0316), Fuzhou
The First Affiliated hospital of Xiamen University-oncology ( Site 0317), Xiamen
Army Medical Center of People's Liberation Army-Oncology Department ( Site 0321), Chongqing
Amethyst Radiotherapy Center ( Site 2102), Florești
Xiangya Hospital Central South University-Oncology department ( Site 0310), Changsha
Hunan Cancer Hospital ( Site 0307), Changsha
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0315), Wuhan
Hubei Cancer Hospital ( Site 0311), Wuhan
Henan Cancer Hospital ( Site 0333), Zhengzhou
Southern Medical University Nanfang Hospital-Department of Oncology ( Site 0336), Guangzhou
West China Hospital of Sichuan University ( Site 0324), Chengdu
ONCOCENTRO APYS-ACEREY ( Site 0203), Viña del Mar
Rambam Health Care Campus-Oncology ( Site 1001), Haifa
Biocenter ( Site 0208), Concepción
James Lind Centro de Investigacion del Cancer ( Site 0202), Temuco
Rabin Medical Center ( Site 1004), Petah Tikva
Sheba Medical Center-ONCOLOGY ( Site 1000), Ramat Gan
Sourasky Medical Center ( Site 1002), Tel Aviv
FALP-UIDO ( Site 0205), Santiago
Centro de Oncología de Precisión ( Site 0209), Santiago
Bradfordhill ( Site 0200), Santiago
Shaare Zedek Medical Center ( Site 1003), Jerusalem
Boston Medical Center ( Site 2829), Boston
University of Massachusetts Chan Medical School ( Site 2815), Worcester
Rutgers Cancer Institute of New Jersey ( Site 2805), New Brunswick
Clinica Adventista Belgrano ( Site 3601), Caba.
Instituto Médico Río Cuarto ( Site 3600), Río Cuarto
Sanatorio Parque ( Site 3602), Rosario
Hospital Nossa Senhora da Conceição ( Site 0111), Porto Alegre
Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0105), Rio de Janeiro
A. C. Camargo Cancer Center-CAPEC ( Site 0102), São Paulo
Fourth Hospital of Hebei Medical University ( Site 0331), Shijiazhuang
Shanxi Cancer Hospital-Pulmonology ( Site 0322), Taiyuan
Masarykuv onkologicky ustav ( Site 3500), Brno
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 3502), Ostrava
Klinikum Chemnitz-Klinik für Innere Medizin IV ( Site 0607), Chemnitz
Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 0703), Athens
Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0706), Athens
Metropolitan Hospital ( Site 0702), Athens
"General Oncology Hospital of Kifissia Agioi Anargiroi-2nd Department of Medical Oncology ( Site 0705)", Nea Kifissia
University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0700), Heraklion
European Interbalkan Medical Center ( Site 0701), Thessaloniki
MEDI-K ( Site 0807), Guatemala City
Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 0802), Guatemala City
Centro Regional de Sub Especialidades Médicas SA ( Site 0801), Quetzaltenango
Centro Medico Integral De Cancerología (CEMIC) ( Site 0805), Quetzaltenango
Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 1101), Rome
National Hospital Organization Shikoku Cancer Center ( Site 1211), Matsuyama
Kurume University Hospital ( Site 1212), Kurume
Kobe Minimally Invasive Cancer Center ( Site 1210), Kobe
Kanagawa Cancer Center ( Site 1204), Yokohama
Miyagi Cancer Center ( Site 1200), Natori-shi
Sendai Kousei Hospital ( Site 1213), Sendai
Niigata Cancer Center Hospital ( Site 1205), Niigata
Kansai Medical University Hospital ( Site 1207), Hirakata
Osaka Medical and Pharmaceutical University Hospital ( Site 1208), Takatsuki
Saitama Prefectural Cancer Center ( Site 1201), Ina-machi
Cancer Institute Hospital of JFCR ( Site 1202), Koto
Showa Medical University Hospital ( Site 1203), Shinagawa
Osaka International Cancer Institute ( Site 1209), Osaka
Arké SMO S.A. de C.V. ( Site 1504), Mexico City
Champalimaud Foundation ( Site 2003), Lisbon
Hospital CUF Descobertas ( Site 2006), Lisbon
Unidade Local de Saude de Santo António - Hospital Santo António ( Site 2004), Porto
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2001), Porto
Centrul Medical Medicover Victoria ( Site 2106), Bucharest
Radiology Therapeutic Center ( Site 2108), Otopeni
Centrul Medical Neolife- Baneasa ( Site 2110), Bucharest
Wilgers Oncology Centre ( Site 2301), Pretoria
Severance Hospital, Yonsei University Health System-Lung Cancer Center ( Site 2403), Seoul
Hospital Universitari Vall d'Hebron ( Site 2501), Barcelona
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2503), Barcelona
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2607), Adana
Ankara Gülhane Eitim ve Aratrma Hastanesi-Oncology ( Site 2602), Ankara
Hacettepe Universitesi-oncology hospital ( Site 2605), Ankara
Memorial Ankara Hastanesi-Medical Oncology ( Site 2609), Ankara
Ankara City Hospital-Medical Oncology ( Site 2601), Ankara
Universal Clinic Oberig-Oncology Center ( Site 2916), Kyiv
Merck Sharp & Dohme LLC
INDUSTRY